Investment Analysts’ Recent Ratings Changes for Bicara Therapeutics (BCAX)

A number of research firms have changed their ratings and price targets for Bicara Therapeutics (NASDAQ: BCAX):

• 1/29/2026 – Bicara Therapeutics is now covered by analysts at Citigroup Inc.. They set an “outperform” rating on the stock.
• 1/29/2026 – Bicara Therapeutics is now covered by analysts at Citizens Jmp. They set a “market perform” rating and a $31.00 price target on the stock.
• 1/15/2026 – Bicara Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research.
• 1/14/2026 – Bicara Therapeutics had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 1/14/2026 – Bicara Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 1/13/2026 – Bicara Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
• 1/9/2026 – Bicara Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/8/2026 – Bicara Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $28.00 price target on the stock.
• 1/8/2026 – Bicara Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $28.00 price target on the stock.
• 12/18/2025 – Bicara Therapeutics was upgraded by analysts at Mizuho to a “hold” rating.
• 12/17/2025 – Bicara Therapeutics is now covered by analysts at Mizuho. They set a “neutral” rating and a $18.00 price target on the stock.

Insider Transactions at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total value of $69,286.80. Following the completion of the transaction, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at approximately $3,803,968.40. The trade was a 1.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 95,922 shares of company stock valued at $1,784,142 in the last three months.

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.